Company / Cash & Equivalents
Sigyn Therapeutics, Inc. Cash & Equivalents History
FY2015-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$500
FY2019
5-year range
$500 / $638.8K
FY2015-FY2019
Trend
-93.3%
vs FY2018
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $638,824 to $500 over the past 4 years.
Based on SEC 10-K filings.
$500 in FY2019.
Declined from $638,824 to $500 over the past 4 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2019, cash & equivalents decreased 93.3% year-over-year.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2019 | $500 | -93.3% |
| FY2018 | $7.5K | -98.8% |
| FY2015 | $638.8K | - |
As of FY2019 · SEC 10-K · Updated Jun 29, 2026